Annual Review 2014
Annual Review 2014

Global Commercial

Our operating structure reflects our ongoing journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to deliver value to patients and our shareholders. Through this evolution, we are enabling greater independence, focus and responsiveness for our commercial businesses.

Global Innovative Pharma Business

Global Innovative Pharma (GIP) is focused on developing, registering and commercializing novel, value-creating medicines that significantly improve patients' lives. These therapeutic areas include inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women's/men's health and include leading brands, such as Xeljanz,® Eliquis® and Lyrica® (U.S. and Japan). GIP has a robust pipeline of medicines in inflammation, cardiovascular / metabolic disease, pain and rare diseases.

Global Vaccines, Oncology and Consumer Healthcare Business

Global Vaccines, Oncology and Consumer Healthcare (VOC) is comprised of three separate, unique businesses that share certain key elements:

  • Each of these businesses is poised for high, organic growth over time

  • Each business requires distinct specializations and operating models in science, talent and market approach

  • Structure provides each business with the dedicated resources required to further strengthen and position it to be a market leader on a global basis

Pfizer Vaccines

Pfizer Vaccines is uniquely positioned as a future leader in the modern vaccine era. This is true both for the development of novel vaccines to prevent infectious diseases of continuing and emerging importance, and for the development of therapeutic vaccines that provide alternative treatments to manage and control disease. Pfizer envisions a shift, with immunizations moving from a one-time intervention in infancy to a solution that fosters health and wellness through one's lifetime. We are an integrated global vaccine organization with end-to-end capabilities ranging from basic research, through process and medical development, to manufacturing and distribution. Our technological and global manufacturing capabilities are state-of-the-art, and our R&D and medical vaccine leaders are global industry innovators, all of whom have had significant vaccine experience in the industry, in academic institutions, as well as in non-governmental and governmental organizations. Collectively, the Pfizer Vaccines team has the experience and steadfast dedication to protect lives with innovative vaccines that fight serious diseases worldwide.

Pfizer Oncology

The goal of Pfizer Oncology is to cure or control cancer by developing breakthrough medicines that represent great value to patients, their caregivers and society. On February 3, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Ibrance® (palbociclib), in combination with letrozole, for the treatment of post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease. Ibrance, an oral kinase inhibitor, was reviewed and approved under the FDA's Breakthrough Therapy designation and Priority Review programs.

In addition to the great strides that have been made over the past year making Xalkori,® Inlyta® and Bosulif® available to patients around the globe, Pfizer Oncology has a promising late-stage pipeline, including investigational drugs being studied for the following indications: Ibrance (palbociclib) for both early and advanced breast cancer and additional solid tumor indications beyond breast cancer through both Pfizer-sponsored and non-sponsored (investigator-initiated) studies, inotuzumab ozogamicin for acute lymphoblastic leukemia and dacomitinib for non-small cell lung cancer. Additionally, Pfizer is working to advance the science in immuno-oncology and actively exploring a variety of novel approaches, including checkpoint modulating antibodies, CAR-T therapies, bi-functional monoclonal antibodies and vaccine-based immunotherapy regimens. Pfizer is also exploring the full potential of combining immunotherapies with its broad oncology portfolio through the company's own development efforts, as well as in collaboration with other partners, working together to improve outcomes for patients with cancer.

Pfizer Consumer Healthcare

Pfizer Consumer Healthcare helps consumers around the world take control of their health and well-being with science-based, differentiated self-care solutions. We are ranked fifth globally among multinational, branded consumer health care companies, and second in our largest markets — the U.S., Canada and China. Our products include over-the-counter (OTC) medicines, supplements and other treatments that are household names and top sellers in their categories. We are the only company with two of the top 10 global OTC brands — Advil® and Centrum.®

Global Established Pharma Business

Global Established Pharma (GEP) is a large and highly diverse business with unique opportunities across portfolios and geographies. It is comprised of three primary product segments with different market dynamics:

  • Peri-LOE products in developed markets — these products have recently lost, or are approaching loss of marketing exclusivity

  • Legacy established products in developed markets — comprised of mature products that have lost marketing exclusivity, and including growth opportunities in developed markets

  • Emerging Markets — comprised of all GEP products sold in emerging markets, and including growth opportunities.

Growth opportunities are another key area of GEP's legacy established products segment, in both developed and emerging markets. These opportunities are comprised of organic and inorganic initiatives, such as partnerships, product enhancements, sterile injectables and biosimilars.